Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772774 | 0.92 | HSD11B1 (0.49) | HSD11B1KDM4E | |
| SCHEMBL4910788 | 0.82 | HRH3 (0.43) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL22163998 | 0.80 | HSD11B1 (0.53) | HSD11B1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1196794 | 0.79 | — | — | |
| SCHEMBL4910222 | 0.79 | GPR183 (0.46) | KDM4EALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL2748651 | 0.78 | KDM4E (0.53) | HSD11B1KDM4EALDH1A1TDP1 | |
| SCHEMBL84934 | 0.78 | PIK3CD (0.59) | HSD11B1KDM4ETDP1 | |
| SCHEMBL1435236 | 0.77 | GPR183 (0.49) | HSD11B1KDM4EALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL772617 | 0.77 | HSD11B1 (0.51) | HSD11B1KDM4EALDH1A1MEN1RAB9A | |
| SCHEMBL4914337 | 0.77 | GNAI3 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113966325-A | Fluorine-containing substituted imidazole salt compound, preparation method thereof, medicinal composition and application thereof | 厦门华绰生物医药科技有限公司 | 2022-01-21 | — | — | CN | claimed |
| CN-111909092-A | Fluorine-containing substituted imidazole salt compound, preparation method thereof, medicinal composition and application thereof | 厦门华绰生物医药科技有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-110612288-A | Substituted imidazole salt compound, preparation method thereof, medicinal composition and application thereof | 厦门华绰生物医药科技有限公司 | 2019-12-24 | — | — | CN | claimed |
| CN-101490058-A | Antiviral agents | GENELABS TECH INC (US) | 2009-07-22 | — | — | CN | claimed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| CN-101103026-A | Bicyclic heteroaryl derivatives for treating viruses | GENELABS INC (US) | 2008-01-09 | — | — | CN | claimed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| CN-113966325-A | Fluorine-containing substituted imidazole salt compound, preparation method thereof, medicinal composition and application thereof | 厦门华绰生物医药科技有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-110612288-A | Substituted imidazole salt compound, preparation method thereof, medicinal composition and application thereof | 厦门华绰生物医药科技有限公司 | 2019-12-24 | — | — | CN | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| EP-0783500-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997029104-A1 | AMINOHETEROCYCLIC COMPOUNDS WITH ANTITHROMBOTIC/ANTICOAGULANT EFFECT | ZENECA LIMITED (GB) | 1997-08-14 | — | — | WO | disclosed |
| WO-1997028129-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |
| EP-0162217-A1 | 1,2,4-Triazacycloalcadiene derivatives | CIBA-GEIGY AG (CH) | 1985-11-27 | — | — | EP | disclosed |
| EP-0157259-A1 | 3-Mercapto-1,2,4-triazacycloalcadiene derivatives | CIBA-GEIGY AG (CH) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | HSD11B1 1282/4885KDM4E 1520/4885ALDH1A1 596/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | HSD11B1 1382/4885KDM4E 2725/4885ALDH1A1 750/4885 |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | HSD11B1 542/4885KDM4E 2663/4885ALDH1A1 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.